Success Metrics

Clinical Success Rate
33.3%

Based on 1 completed trials

Completion Rate
33%(1/3)
Active Trials
2(33%)
Results Posted
200%(2 trials)
Terminated
2(33%)

Phase Distribution

Ph phase_2
6
100%

Phase Distribution

0

Early Stage

6

Mid Stage

0

Late Stage

Phase Distribution6 total trials
Phase 2Efficacy & side effects
6(100.0%)

Highest Phase Reached

Phase 2

Trial Status & Enrollment

Completion Rate

25.0%

1 of 4 finished

Non-Completion Rate

75.0%

3 ended early

Currently Active

2

trials recruiting

Total Trials

6

all time

Status Distribution
Active(2)
Completed(1)
Terminated(3)

Detailed Status

Recruiting2
Terminated2
Withdrawn1
Completed1

Development Timeline

Analytics

Development Status

Total Trials
6
Active
2
Success Rate
33.3%
Most Advanced
Phase 2

Trials by Phase

Phase 26 (100.0%)

Trials by Status

recruiting233%
terminated233%
withdrawn117%
completed117%

Recent Activity

2 active trials
Showing 5 of 6
terminatedphase_2

Study of LN-145, Autologous Tumor Infiltrating Lymphocytes in the Treatment of Patients With Cervical Carcinoma

NCT03108495
recruitingphase_2

Autologous LN-145 in Patients With Metastatic Non-Small-Cell Lung Cancer

NCT04614103
terminatedphase_2

Study of Autologous Tumor Infiltrating Lymphocytes in Patients With Solid Tumors

NCT03645928
recruitingphase_2

TIL Therapy in cSCC and MCC

NCT07288073
completedphase_2

Study of LN-145/LN-145-S1 Autologous Tumor Infiltrating Lymphocytes in the Treatment of Squamous Cell Carcinoma of the Head & Neck

NCT03083873
View all 6 trials

Clinical Trials (6)

Showing 6 of 6 trials
NCT03108495Phase 2

Study of LN-145, Autologous Tumor Infiltrating Lymphocytes in the Treatment of Patients With Cervical Carcinoma

Terminated
NCT04614103Phase 2

Autologous LN-145 in Patients With Metastatic Non-Small-Cell Lung Cancer

Recruiting
NCT03645928Phase 2

Study of Autologous Tumor Infiltrating Lymphocytes in Patients With Solid Tumors

Terminated
NCT07288073Phase 2

TIL Therapy in cSCC and MCC

Recruiting
NCT03083873Phase 2

Study of LN-145/LN-145-S1 Autologous Tumor Infiltrating Lymphocytes in the Treatment of Squamous Cell Carcinoma of the Head & Neck

Completed
NCT03419559Phase 2

Study of Autologous Tumor Infiltrating Lymphocytes (LN-145) In Combo With Durvalumab in Non-Small Cell Lung Cancer

Withdrawn

All 6 trials loaded

Drug Details

Intervention Type
BIOLOGICAL
Total Trials
6